In our hematology program, we are developing CAR-T cells targeting LILRB1, a novel immune inhibitory receptor identified through large-scale cell surface proteomics on patients’ leukemia samples. 

This discovery was enabled by an integrative multi - omics strategy — combining proteomics, high-throughput transcriptomics, and advanced bioinformatics — to ensure that LILRB1 is selectively and consistently expressed across B-cell and monocytic leukemias, and not expressed in healthy tissues beyond B cells and monocytes.

LILRB1 CAR-T strategy offers a promising therapeutic solution for leukemia and lymphoma patients with CD19-negative relapses, lineage-switched leukemias, and monocytic acute myeloid leukemias, while sparing healthy hematopoietic stem cells. With strong preclinical validation, the program is now advancing toward clinical translation.

Read more: Targeting LILRB1 in Refractory Leukemias (PubMed)

Our solid tumor program is focused on liver cancer-directed CAR-T therapy —
a breakthrough approach for liver cancer patients, who are notoriously resistant to conventional treatments. 

Using a locoregional delivery directly into the liver, this strategy has demonstrated remarkable safety and efficacy in murine models, preserving organ integrity while preventing systemic side effects. 

This liver-specific administration maintains full anticancer potency and holds the potential to reshape the immunosuppressive tumor microenvironment, a major obstacle in current liver cancer therapy. 

These findings represent a significant advance in the field and lay a strong foundation for future clinical studies targeting primary liver cancers as well as metastases from other cancers to the liver.